Regeneron Pharmaceuticals in its $250 million all-cash acquisition of Checkmate Pharmaceuticals

On April 19, 2022, Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock.  The proposed acquisition values Checkmate at a total equity value of approximately $250 million.  Wachtell, Lipton, Rosen & Katz served as legal advisor to Regeneron.